Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
173 tokens/sec
GPT-4o
7 tokens/sec
Gemini 2.5 Pro Pro
46 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
38 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

Machine Learning Study of the Extended Drug-target Interaction Network informed by Pain Related Voltage-Gated Sodium Channels (2307.05794v1)

Published 11 Jul 2023 in q-bio.BM and cs.LG

Abstract: Pain is a significant global health issue, and the current treatment options for pain management have limitations in terms of effectiveness, side effects, and potential for addiction. There is a pressing need for improved pain treatments and the development of new drugs. Voltage-gated sodium channels, particularly Nav1.3, Nav1.7, Nav1.8, and Nav1.9, play a crucial role in neuronal excitability and are predominantly expressed in the peripheral nervous system. Targeting these channels may provide a means to treat pain while minimizing central and cardiac adverse effects. In this study, we construct protein-protein interaction (PPI) networks based on pain-related sodium channels and develop a corresponding drug-target interaction (DTI) network to identify potential lead compounds for pain management. To ensure reliable machine learning predictions, we carefully select 111 inhibitor datasets from a pool of over 1,000 targets in the PPI network. We employ three distinct machine learning algorithms combined with advanced NLP-based embeddings, specifically pre-trained transformer and autoencoder representations. Through a systematic screening process, we evaluate the side effects and repurposing potential of over 150,000 drug candidates targeting Nav1.7 and Nav1.8 sodium channels. Additionally, we assess the ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties of these candidates to identify leads with near-optimal characteristics. Our strategy provides an innovative platform for the pharmacological development of pain treatments, offering the potential for improved efficacy and reduced side effects.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (55)
  1. The future of pain research, education, and treatment: a summary of the IOM report “Relieving pain in America: a blueprint for transforming prevention, care, education, and research”. Translational Behavioral Medicine, 2(1):6–8, 01 2012.
  2. The nav1. 7 sodium channel: from molecule to man. Nature Reviews Neuroscience, 14(1):49–62, 2013.
  3. Existence of distinct sodium channel messenger rnas in rat brain. Nature, 320(6058):188–192, 1986.
  4. Chapter 36 - post-traumatic headaches. In Jordan Grafman and Andres M. Salazar, editors, Traumatic Brain Injury, Part II, volume 128 of Handbook of Clinical Neurology, pages 567–578. Elsevier, 2015.
  5. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain, 108(3):237–247, 2004.
  6. Scn9a mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron, 52(5):767–774, 2006.
  7. An scn9a channelopathy causes congenital inability to experience pain. Nature, 444(7121):894–898, 2006.
  8. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 64(6):644–653, 2008.
  9. Voltage-gated sodium channel in grasshopper mice defends against bark scorpion toxin. Science, 342(6157):441–446, 2013.
  10. Infantile pain episodes associated with novel nav1. 9 mutations in familial episodic pain syndrome in japanese families. PLoS One, 11(5):e0154827, 2016.
  11. Cold-aggravated pain in humans caused by a hyperactive nav1. 9 channel mutant. Nature communications, 6(1):10049, 2015.
  12. Familial gain-of-function nav1. 9 mutation in a painful channelopathy. Journal of Neurology, Neurosurgery & Psychiatry, 88(3):233–240, 2017.
  13. The domain ii s4-s5 linker in nav1. 9: a missense mutation enhances activation, impairs fast inactivation, and produces human painful neuropathy. Neuromolecular medicine, 17:158–169, 2015.
  14. Challenges and opportunities for therapeutics targeting the voltage-gated sodium channel isoform nav1. 7. Journal of medicinal chemistry, 62(19):8695–8710, 2019.
  15. Machine learning approaches and databases for prediction of drug–target interaction: a survey paper. Briefings in bioinformatics, 22(1):247–269, 2021.
  16. Predictors of sickness absence in a clinical population with chronic pain. The Journal of Pain, 22(10):1180–1194, 2021.
  17. Machine learning suggests sleep as a core factor in chronic pain. Pain, 162(1):109–123, 2021.
  18. Assigning transcriptomic class in the trigeminal ganglion using multiplex in situ hybridization and machine learning. Pain, 161(9):2212, 2020.
  19. Comparison of machine classification algorithms for fibromyalgia: neuroimages versus self-report. The Journal of Pain, 16(5):472–477, 2015.
  20. Modeling kinase inhibition using highly confident data sets. Journal of Chemical Information and Modeling, 58(5):957–967, 2018.
  21. Modeling of the herg k+ channel blockage using online chemical database and modeling environment (ochem). Molecular Informatics, 36(12):1700074, 2017.
  22. Hergspred: Accurate classification of herg blockers/nonblockers with machine-learning models. Journal of chemical information and modeling, 62(8):1830–1839, 2022.
  23. Virtual screening of drugbank database for herg blockers using topological laplacian-assisted ai models. Computers in biology and medicine, 153:106491, 2023.
  24. Prediction and optimization of nav1. 7 sodium channel inhibitors based on machine learning and simulated annealing. Journal of Chemical Information and Modeling, 60(6):2739–2753, 2020.
  25. Multiple machine learning methods aided virtual screening of nav1. 5 inhibitors. Journal of Cellular and Molecular Medicine, 27(2):266–276, 2023.
  26. Learning with phenotypic similarity improves the prediction of functional effects of missense variants in voltage-gated sodium channels. bioRxiv, pages 2022–09, 2022.
  27. Pep-predna+: A web server for prediction of highly specific peptides targeting voltage-gated na+ channels using machine learning techniques. Computers in Biology and Medicine, 145:105414, 2022.
  28. Towards structure-guided development of pain therapeutics targeting voltage-gated sodium channels. Frontiers in Pharmacology, 13:138, 2022.
  29. Machine learning in chronic pain research: a scoping review. Applied Sciences, 11(7):3205, 2021.
  30. Machine learning in pain medicine: an up-to-date systematic review. Pain and therapy, pages 1–18, 2021.
  31. Machine learning in pain research. Pain, 159(4):623, 2018.
  32. Prescription opioid misuse, abuse, and treatment in the united states: an update. American Journal of Psychiatry, 173(1):18–26, 2016.
  33. Machine-learning analysis of opioid use disorder informed by mor, dor, kor, nor and zor-based interactome networks. Computers in Biology and Medicine, 157:106745, 2023.
  34. Machine-learning repurposing of drugbank compounds for opioid use disorder. Computers in biology and medicine, 160:106921, 2023.
  35. Tidal: Topology-inferred drug addiction learning. Journal of Chemical Information and Modeling, 63(5):1472–1489, 2023.
  36. The role of voltage-gated sodium channels in pain signaling. Physiological reviews, 99(2):1079–1151, 2019.
  37. Voltage-gated sodium channels:(nav) igating the field to determine their contribution to visceral nociception. The Journal of physiology, 596(5):785–807, 2018.
  38. Sodium channel auxiliary subunits. Microbial Physiology, 12(3-4):249–262, 2007.
  39. Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes. Frontiers in pharmacology, 6:263, 2015.
  40. Darren R Flower. Drug design: cutting edge approaches, volume 279. Royal Society of Chemistry, 2002.
  41. Review of primary and secondary erythromelalgia. Clinical and Experimental Dermatology, 44(5):477–482, 2019.
  42. Admetlab 2.0: an integrated online platform for accurate and comprehensive predictions of admet properties. Nucleic Acids Research, 49(W1):W5–W14, 2021.
  43. Greg Landrum et al. Rdkit: A software suite for cheminformatics, computational chemistry, and predictive modeling. Greg Landrum, 8, 2013.
  44. Lowering side effects of nsaid usage in osteoarthritis: recent attempts at minimizing dosage. Expert opinion on pharmacotherapy, 19(2):93–102, 2018.
  45. Opioid pharmacology. Pain physician, 11(2S):S133, 2008.
  46. Amitriptyline: a review of its pharmacological properties and therapeutic use in chronic pain states. Drugs & aging, 8:459–476, 1996.
  47. Implications and mechanism of action of gabapentin in neuropathic pain. Archives of pharmacal research, 36:237–251, 2013.
  48. Using autodock 4 and autodock vina with autodocktools: a tutorial. The Scripps Research Institute Molecular Graphics Laboratory, 10550(92037):1000, 2012.
  49. Comparability of mixed ic50 data–a statistical analysis. PloS one, 8(4):e61007, 2013.
  50. Extracting predictive representations from hundreds of millions of molecules. The journal of physical chemistry letters, 12(44):10793–10801, 2021.
  51. Learning continuous and data-driven molecular descriptors by translating equivalent chemical representations. Chemical science, 10(6):1692–1701, 2019.
  52. Ggl-tox: geometric graph learning for toxicity prediction. Journal of chemical information and modeling, 61(4):1691–1700, 2021.
  53. Boosting tree-assisted multitask deep learning for small scientific datasets. Journal of chemical information and modeling, 60(3):1235–1244, 2020.
  54. Support-vector networks. Machine learning, 20:273–297, 1995.
  55. Leo Breiman. Random forests. Machine learning, 45:5–32, 2001.
Citations (2)
View on Semantic Scholar

Summary

We haven't generated a summary for this paper yet.

Ai Sparkles Streamline Icon: https://streamlinehq.com Summarize Now